Monthly Archives: April 2015

The Oil Merger of the Decade: Shell to Buy BG Group

According to a statement by BG Group, Royal Dutch Shell is considering a “super-merger” with BG to expand its gas production, which would mark the biggest merger of the year.

FedEx Looks to Become Major European Player with TNT Express Acquisition

FedEx has agreed to acquire European shipping and delivery competitor TNT Express (TNT). The $4.8 billion deal must still receive approval from European regulators, a status that UPS failed to achieve when its proposed acquisition of TNT was blocked by these same regulators in 2013. UPS was unable to satisfy regulator’s antitrust concerns because of […]

Life Time Fitness Acquired in $4 Billion Buyout

Continuing their leveraged buyout partnership, private equity firms Leonard Green & Partners and TPG Capital recently announced an agreement to buy gym operator Life Time Fitness for about $4 billion. The two firms previously worked together to acquire retailer J.Crew in 2010 and Petco in 2006.

A New Leader in Combatting C.N.S. Disorders

On Monday, March 30, Teva Pharmaceutical Industries Ltd. announced that it would be acquiring Auspex Pharmaceuticals for $3.2 billion. As a result of the acquisition, shares of Auspex climbed from $29.60 (41.7 percent) to $100.51 while Teva shares increased by $1.67 (2.7 percent) to $63.65. This major increase in the value of the shares for […]

Potential CIT and OneWest Bank Merger Faces Public Hearing

A proposed merger between OneWest Bank and CIT Group is facing increased scrutiny from federal banking regulators amidst concerns that the merged bank could hinder community-lending practices under the Community Reinvestment Act (CRA).

Lunch with Professor Michael Katz: The Future of Payment Platforms and the Legal Frontier of Digital Currency

On March 5, 2015, Professor Michael Katz, Sarin Chair in Strategy and Leadership, Director of the Center for Telecommunications and Digital Convergence, and professor of business at the UC Berkeley Haas School of Business, gave the lunchtime keynote address for the Berkeley Business Law Journal’s “Bits Bites Plastic: The New World of Electronic Payments and […]

Victories Over Amgen Bring Sandoz Closer to Launching First U.S. Biosimilar

On March 6, 2015, the FDA approved Zarxio, a biologic pharmaceutical produced by Novartis’ generic drug unit—Sandoz—that is biosimilar to Amgen’s Neupogen. Now, after overcoming two important challenges, Sandoz is poised to bring the first biosimilar approved under the Affordable Care Act to the U.S. market.

A Giant Merger in the Generic Drug Industry

In accordance with its 8-K filing of Auspex Pharmaceuticals, Inc. (“Auspex”) with the U.S. Securities and Exchange Commission on March 30, 2015, Teva Pharmaceuticals Industries Ltd. (“Teva”), entered into a merger agreement with Auspex at a purchase price of $101 per share. The total amount of purchase will be about $3.2 billion.